8-K: Cocrystal Pharma's CDI-988 Shows Favorable Phase 1 Safety

Cocrystal Pharma announced positive safety and tolerability data from its Phase 1 study of pan-viral inhibitor CDI-988, supporting its continued development for norovirus.

Summary

• Cocrystal Pharma presented favorable safety and tolerability data from a randomized, double-blinded, placebo-controlled Phase 1 study of its oral, direct-acting pan-viral inhibitor CDI-988.
• The study included single-ascending dose (SAD) and multiple-ascending dose (MAD) cohorts, with CDI-988 doses ranging from 100 mg to 1200 mg.
• All tested doses of CDI-988 were well tolerated, demonstrating a favorable safety profile.
• Treatment-emergent adverse events (TEAEs) for CDI-988 subjects were 28% (10/36) in SAD cohorts compared to 40% (4/10) for placebo subjects.
• In MAD cohorts, TEAEs for CDI-988 subjects were 53% (19/36) compared to 92% (11/12) for placebo subjects.
• Headache was the most common adverse event reported.
• All subjects in SAD cohorts and all but one in MAD cohorts completed the study.
• No severe treatment-emergent adverse events, clinically relevant ECG changes, or clinically significant pathology results were reported.
• The company plans to initiate a Phase 1b challenge study with CDI-988 in norovirus-infected healthy subjects later in 2025.

Sentiment

Score: 8

Explanation: The filing reports positive Phase 1 safety and tolerability data for CDI-988, a drug targeting a significant unmet medical need (norovirus). The lower adverse event rates compared to placebo and clear next steps for clinical development contribute to a strong positive sentiment, despite the inherent risks of drug development and the need for future capital.

Positives

• All CDI-988 doses (100 mg to 1200 mg) were well tolerated in the Phase 1 study.
• CDI-988 demonstrated a favorable safety profile across all dose levels tested.
• Treatment-emergent adverse event rates for CDI-988 were lower than placebo in both SAD (28% vs. 40%) and MAD (53% vs. 92%) cohorts.
• The study reported no severe treatment-emergent adverse events, no clinically relevant ECG changes, and no clinically significant pathology results.
• High study completion rates, with all SAD subjects and all but one MAD subject completing the study.
• CDI-988 targets a highly conserved region in 3CL viral proteases, offering broad-spectrum coverage against norovirus genogroups, including GII.4 and GII.17.
• The drug addresses a critical unmet medical need, as there are currently no approved norovirus treatments or vaccines.

Negatives

• Headache was identified as the most common adverse event, though overall adverse event rates were favorable.

Risks

• Need for additional capital to fund operations over the next 12 months.
• Risks related to obtaining regulatory approval for and proceeding with clinical trials, including recruiting volunteers and procuring materials.
• Uncertainty regarding the results of future clinical studies.
• Risks associated with the performance of the company's and collaboration partners' technology and software.
• General risks inherent in clinical studies.
• Dependence on receipt of regulatory approvals for product development.
• Potential for regulatory changes that could impact development programs.
• Risk of competitors developing effective treatments and/or vaccines.
• Potential for mutations in target viruses that may lead to variants resistant to developed product candidates.
• Impact of government policies and actions, such as those affecting the FDA or tariffs, which may cause delays or increased costs.

Future Outlook

Cocrystal Pharma expects to initiate a Phase 1b challenge study with CDI-988 in norovirus-infected healthy subjects later in 2025, continuing its clinical development for norovirus prophylaxis and treatment.

Management Comments

• "Consistent with interim results from the Phase 1 study, CDI-988 was well-tolerated with a favorable safety profile across all dose levels tested in this study."
• "Our plan to continue CDI-988s clinical development for norovirus is particularly relevant for the military, where this highly transmissible pathogen poses significant operational and economic risks."
• "In confined settings such as naval vessels and military installations, norovirus can rapidly spread, causing debilitating gastrointestinal symptoms that could compromise mission readiness."
• "The absence of approved norovirus treatments or vaccines creates a critical unmet medical need."

Industry Context

Norovirus is a common, highly contagious virus causing acute gastroenteritis, with no approved treatments or vaccines, presenting a critical unmet medical need. It poses significant operational and economic risks, particularly in confined settings like military installations, and is estimated to cost society approximately $60 billion annually worldwide. CDI-988's broad-spectrum mechanism targeting viral replication offers a promising new approach to outbreak prevention and management.

Stakeholder Impact

• Shareholders: Positive clinical data may increase investor confidence and potentially lead to share price appreciation.
• Patients: Offers a potential new prophylactic and therapeutic intervention for norovirus infections, addressing a critical unmet medical need.
• Military personnel: Could significantly reduce the impact of norovirus outbreaks in confined settings, improving mission readiness.
• Healthcare providers: Provides a potential new tool for managing and preventing norovirus outbreaks in various community settings.

Next Steps

• Initiate a Phase 1b challenge study with CDI-988 in norovirus-infected healthy subjects later in 2025.

Key Dates

Recommendation

The favorable safety and tolerability profile of CDI-988 in its Phase 1 study, coupled with the significant unmet medical need for norovirus treatments, positions Cocrystal Pharma for continued clinical development. The data suggests a promising therapeutic candidate, warranting a positive outlook for long-term investors despite inherent risks in drug development and the stated need for future capital.

Keywords

Cocrystal Pharma, CDI-988, norovirus, antiviral, Phase 1, clinical trial, drug development, biotechnology, protease inhibitor, MHSRS, COCP